Compare PLETHICO PHARMA with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs ASTRAZENECA PHARMA - Comparison Results

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA ASTRAZENECA PHARMA PLETHICO PHARMA/
ASTRAZENECA PHARMA
 
P/E (TTM) x -1.1 86.7 - View Chart
P/BV x 0.0 24.4 0.1% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 PLETHICO PHARMA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
ASTRAZENECA PHARMA
Mar-18
PLETHICO PHARMA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs3951,278 30.9%   
Low Rs31883 3.5%   
Sales per share (Unadj.) Rs604.4228.4 264.6%  
Earnings per share (Unadj.) Rs32.510.4 313.4%  
Cash flow per share (Unadj.) Rs51.316.3 315.7%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs473.698.8 479.4%  
Shares outstanding (eoy) m34.0825.00 136.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.44.7 7.5%   
Avg P/E ratio x6.6104.2 6.3%  
P/CF ratio (eoy) x4.266.4 6.2%  
Price / Book Value ratio x0.510.9 4.1%  
Dividend payout %00-   
Avg Mkt Cap Rs m7,26227,008 26.9%   
No. of employees `000NA1.4 0.0%   
Total wages/salary Rs m1,5961,535 104.0%   
Avg. sales/employee Rs ThNM4,210.9-  
Avg. wages/employee Rs ThNM1,132.2-  
Avg. net profit/employee Rs ThNM191.1-  
INCOME DATA
Net Sales Rs m20,5985,710 360.7%  
Other income Rs m386123 315.4%   
Total revenues Rs m20,9845,833 359.8%   
Gross profit Rs m2,818463 608.7%  
Depreciation Rs m642147 435.8%   
Interest Rs m1,5930-   
Profit before tax Rs m969438 221.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-138179 -77.4%   
Profit after tax Rs m1,107259 427.2%  
Gross profit margin %13.78.1 168.7%  
Effective tax rate %-14.340.8 -35.0%   
Net profit margin %5.44.5 118.4%  
BALANCE SHEET DATA
Current assets Rs m18,8773,209 588.2%   
Current liabilities Rs m11,8962,070 574.8%   
Net working cap to sales %33.920.0 169.8%  
Current ratio x1.61.6 102.3%  
Inventory Days Days3672 49.7%  
Debtors Days Days19835 566.5%  
Net fixed assets Rs m9,861790 1,247.7%   
Share capital Rs m34150 681.4%   
"Free" reserves Rs m12,3312,419 509.7%   
Net worth Rs m16,1392,469 653.6%   
Long term debt Rs m4,7060-   
Total assets Rs m33,1464,605 719.7%  
Interest coverage x1.6NM-  
Debt to equity ratio x0.30-  
Sales to assets ratio x0.61.2 50.1%   
Return on assets %8.15.6 144.8%  
Return on equity %6.910.5 65.4%  
Return on capital %12.317.7 69.3%  
Exports to sales %21.40-   
Imports to sales %15.20-   
Exports (fob) Rs m4,402NA-   
Imports (cif) Rs m3,136NA-   
Fx inflow Rs m4,402300 1,469.7%   
Fx outflow Rs m3,1842,015 158.0%   
Net fx Rs m1,219-1,715 -71.0%   
CASH FLOW
From Operations Rs m2,43788 2,772.9%  
From Investments Rs m-6,265-94 6,693.1%  
From Financial Activity Rs m2,490NA-  
Net Cashflow Rs m-1,337-6 23,458.9%  

Share Holding

Indian Promoters % 82.7 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 4.3 0.3 1,433.3%  
FIIs % 5.5 15.7 35.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 9.1 82.4%  
Shareholders   10,665 12,856 83.0%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   NOVARTIS  JUBILANT LIFE SCIENCES  BIOCON   IPCA LABS  NATCO PHARMA  

Compare PLETHICO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Witness Selling, Key Q2FY20 Results, and Top Cues in Focus Today(Pre-Open)

India share markets ended their day deep in the red yesterday. At the closing bell yesterday, the BSE Sensex stood lower by 334 points (down 0.9%).

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 66.7% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 91 m (down 66.7% YoY). Sales on the other hand came in at Rs 2 bn (down 1.8% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA - GSK PHARMA COMPARISON

COMPARE PLETHICO PHARMA WITH

MARKET STATS